- Home
- HYLN vs CTNM Comparison
HYLN vs CTNM Comparison
Compare HYLN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYLN
- CTNM
- Stock Information
- Founded
- HYLN 2018
- CTNM 2009
- Country
- HYLN United States
- CTNM United States
- Employees
- HYLN N/A
- CTNM N/A
- Industry
- HYLN Construction/Ag Equipment/Trucks
- CTNM
- Sector
- HYLN Consumer Discretionary
- CTNM
- Exchange
- HYLN Nasdaq
- CTNM Nasdaq
- Market Cap
- HYLN 396.5M
- CTNM 328.1M
- IPO Year
- HYLN N/A
- CTNM 2024
- Fundamental
- Price
- HYLN $1.70
- CTNM $10.69
- Analyst Decision
- HYLN Strong Buy
- CTNM Strong Buy
- Analyst Count
- HYLN 1
- CTNM 5
- Target Price
- HYLN $5.00
- CTNM $22.20
- AVG Volume (30 Days)
- HYLN 1.9M
- CTNM 106.2K
- Earning Date
- HYLN 11-11-2025
- CTNM 10-30-2025
- Dividend Yield
- HYLN N/A
- CTNM N/A
- EPS Growth
- HYLN N/A
- CTNM N/A
- EPS
- HYLN N/A
- CTNM N/A
- Revenue
- HYLN $4,272,000.00
- CTNM N/A
- Revenue This Year
- HYLN $261.63
- CTNM N/A
- Revenue Next Year
- HYLN $219.63
- CTNM N/A
- P/E Ratio
- HYLN N/A
- CTNM N/A
- Revenue Growth
- HYLN 124.55
- CTNM N/A
- 52 Week Low
- HYLN $1.11
- CTNM $3.35
- 52 Week High
- HYLN $4.10
- CTNM $19.21
- Technical
- Relative Strength Index (RSI)
- HYLN 36.02
- CTNM 46.61
- Support Level
- HYLN $1.93
- CTNM $10.07
- Resistance Level
- HYLN $2.20
- CTNM $11.75
- Average True Range (ATR)
- HYLN 0.17
- CTNM 0.71
- MACD
- HYLN -0.07
- CTNM -0.01
- Stochastic Oscillator
- HYLN 10.43
- CTNM 37.50
About HYLN Hyliion Holdings Corp.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.